Priority review
Priority review is a program of the United States Food and Drug Administration (FDA) to expedite the review process for drugs that are expected to have a particularly great impact on the treatment of a disease. The priority review voucher program is a program that grants a voucher for priority review to a drug developer as an incentive to develop treatments for disease indications with limited profitability.
AlirocumabAllopregnanoloneAlpelisibAmicus TherapeuticsAmikacinAvelumabAxicabtagene ciloleucelBaloxavir_marboxilBelantamab mafodotinBreakthrough therapyBrexucabtagene autoleucelCDK inhibitorCapmatinibCasimersenCefiderocolCemiplimabCerliponase alfaCopanlisibCrizanlizumabDarolutamideDecitabine/cedazuridineDefibrotideDengue vaccineDupilumabElapegademaseElexacaftor/tezacaftor/ivacaftorEnfortumab vedotinEntrectinibEvinacumabFast track (FDA)FedratinibFenfluramineFilgotinibFlortaucipir (18F)Food and Drug AdministrationFood and Drug Administration Amendments Act of 2007Food and Drug Administration Safety and Innovation ActFosdenopterinFostemsavirG1 Therapeutics
Link from a Wikipage to another Wikipage
primaryTopic
Priority review
Priority review is a program of the United States Food and Drug Administration (FDA) to expedite the review process for drugs that are expected to have a particularly great impact on the treatment of a disease. The priority review voucher program is a program that grants a voucher for priority review to a drug developer as an incentive to develop treatments for disease indications with limited profitability.
has abstract
Priority review is a program o ...... ures was added to the program.
@en
Link from a Wikipage to an external page
Wikipage page ID
16,460,004
page length (characters) of wiki page
Wikipage revision ID
1,023,815,961
Link from a Wikipage to another Wikipage
wikiPageUsesTemplate
subject
comment
Priority review is a program o ...... ns with limited profitability.
@en
label
Priority review
@en